India’s Breathe Well-being raises $5.5m for diabetes reversal appDigital health startup Breathe Well-being has raised $5.5 million in first-round financing, which it will use to scale Share XIndia’s Breathe Well-being raises $5.5m for diabetes reversal apphttps://pharmaphorum.com/news/indias-breathe-well-being-raises-5-5m-for-diabetes-reversal-app/
Lilly grabs glucose-sensing insulin tech, buying Protomer in $1bn dealEli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must Share XLilly grabs glucose-sensing insulin tech, buying Protomer in $1bn dealhttps://pharmaphorum.com/news/lilly-grabs-glucose-sensing-insulin-tech-buying-protomer-in-1bn-deal/
Bayer’s finerenone gets FDA nod for diabetic kidney diseaseBayer’s big investment in time and money on the development of finerenone for chronic kidney disease (CKD) in Share XBayer’s finerenone gets FDA nod for diabetic kidney diseasehttps://pharmaphorum.com/news/bayers-finerenone-gets-fda-nod-for-diabetic-kidney-disease/
FDA rejects Provention’s type 1 diabetes drug teplizumabThe FDA indicated something was not well with Provention Bio’s filing for type 1 diabetes therapy teplizumab in Share XFDA rejects Provention’s type 1 diabetes drug teplizumabhttps://pharmaphorum.com/news/fda-rejects-proventions-type-1-diabetes-drug-teplizumab/
Carbon Health buys virtual diabetes clinic firm Steady HealthUS healthcare group Carbon Health has made a move into digital care for patients with chronic conditions, buying Share XCarbon Health buys virtual diabetes clinic firm Steady Healthhttps://pharmaphorum.com/news/carbon-health-buys-virtual-diabetes-clinic-firm-steady-health/
Trial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatideEli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate Share XTrial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatidehttps://pharmaphorum.com/news/final-trial-win-sets-up-filings-for-lillys-diabetes-blockbuster-hope-tirzepatide/
Arecor hopes London stock market float will raise profile of insulin productsUK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to Share XArecor hopes London stock market float will raise profile of insulin productshttps://pharmaphorum.com/news/arecor-hopes-london-stock-market-float-will-raise-profile-of-insulin-products/
Tackling diabetes & ALS with cell therapyIsraeli company Kadimastem is developing regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells Share XTackling diabetes & ALS with cell therapyhttps://pharmaphorum.com/views-and-analysis/tackling-diabetes-als-with-cell-therapy/
Novo Nordisk ups forecasts after Q1 profit boostAfter an indifferent period Novo Nordisk has kicked off 2021 on the front foot, raising its financial forecast Share XNovo Nordisk ups forecasts after Q1 profit boosthttps://pharmaphorum.com/news/novo-nordisk-ups-forecasts-after-q1-profit-boost/
